Compare $NVAX vs $VRDN | Chartloom

Compare

$NVAX vs $VRDN

Novavax Inc · Viridian Therapeutics Inc

NVAX

Novavax Inc

VRDN

Viridian Therapeutics Inc

Compare $NVAX vs $VRDN

Comparing Novavax Inc and Viridian Therapeutics Inc

NVAXNovavax Inc

VRDNViridian Therapeutics Inc

NVAXNovavax Inc

Market cap

$2.10B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

10.28x

Rev growth (TTM)

-61.6%

YTD performance

78.8%

52W performance

43.3%

FCF yield

-2.0%

VRDNViridian Therapeutics Inc

Market cap

$2.06B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

14.59x

Rev growth (TTM)

23220.3%

YTD performance

-39.2%

52W performance

-12.6%

FCF yield

-16.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NVAX

VRDN

Detailed metrics comparison

NVAX

Novavax Inc

VRDN

Viridian Therapeutics Inc

Market Cap

NVAX$2.10B

VRDN$2.06B

Enterprise Value

NVAX$2.20B

VRDN$2.25B

Price

NVAX$12.75

VRDN$18.66

P/E Ratio

NVAXN/A

VRDNN/A

P/S Ratio

NVAX5.07x

VRDN28.97x

EV/Sales

NVAX5.32x

VRDN31.65x

EV/EBITDA

NVAX4.05x

VRDN0.00x

P/B Ratio

NVAX45.86x

VRDN3.58x

P/FCF Ratio

NVAXN/A

VRDNN/A

EV/FCF

NVAX-51.40x

VRDN-6.72x

PEG Ratio

NVAXN/A

VRDNN/A

Forward P/E (NTM)

NVAXN/A

VRDNN/A

Forward P/S (NTM)

NVAX10.28x

VRDN14.59x

Revenue (TTM)

NVAX$414M

VRDN$71M

Revenue Growth (YoY)

NVAX-61.6%

VRDN23220.3%

Forward Rev Growth

NVAX-25.1%

VRDN729.0%

Gross Margin (TTM)

NVAX79.2%

VRDN2.4%

Operating Margin (TTM)

NVAX0.0%

VRDN0.0%

EBITDA Margin (TTM)

NVAX-24.0%

VRDN-569.0%

Net Margin (TTM)

NVAX-59.9%

VRDN-544.1%

FCF Margin (TTM)

NVAX-10.4%

VRDN-471.0%

Net Income (TTM)

NVAX$-248M

VRDN$-387M

FCF (TTM)

NVAX$-43M

VRDN$-335M

EPS (TTM)

NVAX-$1.51

VRDN-$3.59

ROE (TTM)

NVAX283.1%

VRDN-6135.0%

ROA (TTM)

NVAX-2275.0%

VRDN-4603.0%

ROIC (TTM)

NVAX40.0%

VRDN-5041.0%

Cash

NVAX$191M

VRDN$165M

Debt

NVAX$297M

VRDN$356M

Net Cash/Debt

NVAX$-106M

VRDN$-191M

Current Ratio (TTM)

NVAX2.33x

VRDN16.95x

Quick Ratio (TTM)

NVAX2.23x

VRDN16.56x

Debt/Equity (TTM)

NVAX6.07x

VRDN0.54x

Debt/Assets (TTM)

NVAX0.0%

VRDN0.0%

Interest Coverage (TTM)

NVAXN/A

VRDNN/A

Net Debt/EBITDA (TTM)

NVAX0.00x

VRDN0.00x

Beta

NVAX2.81

VRDN1.11

52W Performance

NVAX43.3%

VRDN-12.6%

YTD Performance

NVAX78.8%

VRDN-39.2%

% from 52W High

NVAX-4.7%

VRDN-45.6%

% from 52W Low

NVAX105.6%

VRDN41.6%

Asset Turnover (TTM)

NVAX0.38x

VRDN0.08x

FCF Yield (TTM)

NVAX-2.0%

VRDN-16.3%

Earnings Yield (TTM)

NVAX-11.8%

VRDN-18.8%

Dividend Yield (TTM)

NVAXN/A

VRDNN/A

Rule of 40

NVAX-72.0

VRDN22,749.3

EV/GP/RG

NVAXN/A

VRDN8.67

Ticker research

View NVAX research View VRDN research

Metric	NVAX Novavax Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.10B	$2.06B
Enterprise Value	$2.20B	$2.25B
Price	$12.75	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	28.97x
EV/Sales	5.32x	31.65x
EV/EBITDA	4.05x	0.00x
P/B Ratio	45.86x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	14.59x
Revenue & Growth
Revenue (TTM)	$414M	$71M
Revenue Growth (YoY)	-61.6%	23220.3%
Forward Rev Growth	-25.1%	729.0%
Profitability
Gross Margin (TTM)	79.2%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	-569.0%
Net Margin (TTM)	-59.9%	-544.1%
FCF Margin (TTM)	-10.4%	-471.0%
Net Income (TTM)	$-248M	$-387M
FCF (TTM)	$-43M	$-335M
EPS (TTM)	-$1.51	-$3.59
ROE (TTM)	283.1%	-6135.0%
ROA (TTM)	-2275.0%	-4603.0%
ROIC (TTM)	40.0%	-5041.0%
Financial Health
Cash	$191M	$165M
Debt	$297M	$356M
Net Cash/Debt	$-106M	$-191M
Current Ratio (TTM)	2.33x	16.95x
Quick Ratio (TTM)	2.23x	16.56x
Debt/Equity (TTM)	6.07x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	1.11
52W Performance	43.3%	-12.6%
YTD Performance	78.8%	-39.2%
% from 52W High	-4.7%	-45.6%
% from 52W Low	105.6%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.08x
FCF Yield (TTM)	-2.0%	-16.3%
Earnings Yield (TTM)	-11.8%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View NVAX research	View VRDN research

Valuation

P/S Ratio

NVAX

5.07x

VRDN

28.97x

EV/FCF

NVAX

-51.40x

VRDN

-6.72x

Growth & revenue

Revenue Growth TTM

VRDN

23220.3%

NVAX

-61.6%

Forward Revenue Growth

VRDN

729.0%

NVAX

-25.1%

Profitability & performance

Gross Margin

NVAX

79.2%

VRDN

2.4%

ROE

NVAX

283.1%

VRDN

-6135.0%

FCF Yield %

NVAX

-2.0%

VRDN

-16.3%

52-Week Performance

NVAX

43.3%

VRDN

-12.6%

Detailed metrics comparison

NVAX

Novavax Inc

VRDN

Viridian Therapeutics Inc

Market Cap

NVAX$2.10B

VRDN$2.06B

Enterprise Value

NVAX$2.20B

VRDN$2.25B

Price

NVAX$12.75

VRDN$18.66

P/E Ratio

NVAXN/A

VRDNN/A

P/S Ratio

NVAX5.07x

VRDN28.97x

EV/Sales

NVAX5.32x

VRDN31.65x

EV/EBITDA

NVAX4.05x

VRDN0.00x

P/B Ratio

NVAX45.86x

VRDN3.58x

P/FCF Ratio

NVAXN/A

VRDNN/A

EV/FCF

NVAX-51.40x

VRDN-6.72x

PEG Ratio

NVAXN/A

VRDNN/A

Forward P/E (NTM)

NVAXN/A

VRDNN/A

Forward P/S (NTM)

NVAX10.28x

VRDN14.59x

Revenue (TTM)

NVAX$414M

VRDN$71M

Revenue Growth (YoY)

NVAX-61.6%

VRDN23220.3%

Forward Rev Growth

NVAX-25.1%

VRDN729.0%

Gross Margin (TTM)

NVAX79.2%

VRDN2.4%

Operating Margin (TTM)

NVAX0.0%

VRDN0.0%

EBITDA Margin (TTM)

NVAX-24.0%

VRDN-569.0%

Net Margin (TTM)

NVAX-59.9%

VRDN-544.1%

FCF Margin (TTM)

NVAX-10.4%

VRDN-471.0%

Net Income (TTM)

NVAX$-248M

VRDN$-387M

FCF (TTM)

NVAX$-43M

VRDN$-335M

EPS (TTM)

NVAX-$1.51

VRDN-$3.59

ROE (TTM)

NVAX283.1%

VRDN-6135.0%

ROA (TTM)

NVAX-2275.0%

VRDN-4603.0%

ROIC (TTM)

NVAX40.0%

VRDN-5041.0%

Cash

NVAX$191M

VRDN$165M

Debt

NVAX$297M

VRDN$356M

Net Cash/Debt

NVAX$-106M

VRDN$-191M

Current Ratio (TTM)

NVAX2.33x

VRDN16.95x

Quick Ratio (TTM)

NVAX2.23x

VRDN16.56x

Debt/Equity (TTM)

NVAX6.07x

VRDN0.54x

Debt/Assets (TTM)

NVAX0.0%

VRDN0.0%

Interest Coverage (TTM)

NVAXN/A

VRDNN/A

Net Debt/EBITDA (TTM)

NVAX0.00x

VRDN0.00x

Beta

NVAX2.81

VRDN1.11

52W Performance

NVAX43.3%

VRDN-12.6%

YTD Performance

NVAX78.8%

VRDN-39.2%

% from 52W High

NVAX-4.7%

VRDN-45.6%

% from 52W Low

NVAX105.6%

VRDN41.6%

Asset Turnover (TTM)

NVAX0.38x

VRDN0.08x

FCF Yield (TTM)

NVAX-2.0%

VRDN-16.3%

Earnings Yield (TTM)

NVAX-11.8%

VRDN-18.8%

Dividend Yield (TTM)

NVAXN/A

VRDNN/A

Rule of 40

NVAX-72.0

VRDN22,749.3

EV/GP/RG

NVAXN/A

VRDN8.67

Ticker research

View NVAX research View VRDN research

Metric	NVAX Novavax Inc	VRDN Viridian Therapeutics Inc
Market & Valuation
Market Cap	$2.10B	$2.06B
Enterprise Value	$2.20B	$2.25B
Price	$12.75	$18.66
P/E Ratio	N/A	N/A
P/S Ratio	5.07x	28.97x
EV/Sales	5.32x	31.65x
EV/EBITDA	4.05x	0.00x
P/B Ratio	45.86x	3.58x
P/FCF Ratio	N/A	N/A
EV/FCF	-51.40x	-6.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	10.28x	14.59x
Revenue & Growth
Revenue (TTM)	$414M	$71M
Revenue Growth (YoY)	-61.6%	23220.3%
Forward Rev Growth	-25.1%	729.0%
Profitability
Gross Margin (TTM)	79.2%	2.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-24.0%	-569.0%
Net Margin (TTM)	-59.9%	-544.1%
FCF Margin (TTM)	-10.4%	-471.0%
Net Income (TTM)	$-248M	$-387M
FCF (TTM)	$-43M	$-335M
EPS (TTM)	-$1.51	-$3.59
ROE (TTM)	283.1%	-6135.0%
ROA (TTM)	-2275.0%	-4603.0%
ROIC (TTM)	40.0%	-5041.0%
Financial Health
Cash	$191M	$165M
Debt	$297M	$356M
Net Cash/Debt	$-106M	$-191M
Current Ratio (TTM)	2.33x	16.95x
Quick Ratio (TTM)	2.23x	16.56x
Debt/Equity (TTM)	6.07x	0.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.81	1.11
52W Performance	43.3%	-12.6%
YTD Performance	78.8%	-39.2%
% from 52W High	-4.7%	-45.6%
% from 52W Low	105.6%	41.6%
Efficiency & Yields
Asset Turnover (TTM)	0.38x	0.08x
FCF Yield (TTM)	-2.0%	-16.3%
Earnings Yield (TTM)	-11.8%	-18.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-72.0	22,749.3
EV/GP/RG	N/A	8.67
Ticker research	View NVAX research	View VRDN research